Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line

R J Marshall1, T P Flanigan

  • 1Case Western Reserve School of Medicine, Cleveland, Ohio.

Insights

Paromomycin shows promise for treating Cryptosporidium parvum infections in AIDS patients. This nonabsorbable aminoglycoside significantly inhibited parasite infection in human enterocyte cell lines in vitro.

Area of Science:

  • Medical Parasitology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Cryptosporidium parvum causes severe enteritis in AIDS patients, lacking effective treatments.
  • Paromomycin is an aminoglycoside effective against other intestinal protozoa.

Purpose of the Study:

  • To evaluate the in vitro efficacy of paromomycin against Cryptosporidium parvum infection.

Main Methods:

  • Assessed paromomycin's inhibition of C. parvum in a human enterocyte cell line.
  • Tested concentrations ranging from 50 to 5000 µg/ml over 24 hours.

Main Results:

  • Paromomycin demonstrated dose-dependent inhibition of C. parvum infection.
  • Concentrations >1000 µg/ml achieved >85% inhibition (P < .001).

Conclusions:

  • Paromomycin effectively inhibits C. parvum in vitro.
  • Clinical trials of paromomycin for AIDS-associated cryptosporidiosis are recommended.